Understanding and addressing anti-drug antibody formation in tumor necrosis factor-α inhibitor therapy for ankylosing spondylitis.
作者信息
Kim Tae-Jong
机构信息
Department of Rheumatology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.
出版信息
J Rheum Dis. 2025 Jul 1;32(3):151-153. doi: 10.4078/jrd.2025.0067. Epub 2025 Jun 18.
Abstract
摘要
相似文献
1
Understanding and addressing anti-drug antibody formation in tumor necrosis factor-α inhibitor therapy for ankylosing spondylitis.强直性脊柱炎肿瘤坏死因子-α抑制剂治疗中抗药物抗体形成的理解与应对
J Rheum Dis. 2025 Jul 1;32(3):151-153. doi: 10.4078/jrd.2025.0067. Epub 2025 Jun 18.
2
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.阿达木单抗、依那西普和英夫利昔单抗治疗强直性脊柱炎：系统评价与经济学评估
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
3
Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.用于强直性脊柱炎和非放射学中轴型脊柱关节炎的肿瘤坏死因子-α抑制剂：一项系统评价和经济学评估
Health Technol Assess. 2016 Feb;20(9):1-334, v-vi. doi: 10.3310/hta20090.
4
Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?类风湿关节炎、银屑病关节炎和强直性脊柱炎患者接受抗肿瘤坏死因子α治疗的恶性肿瘤单中心系列研究及随机对照试验的系统评价：是否需要更全面的筛查程序？
Arthritis Rheum. 2009 Jun 15;61(6):801-12. doi: 10.1002/art.24506.
5
The validity and reliability of quality of life questionnaires in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and meta-analysis.强直性脊柱炎和非放射学中轴型脊柱关节炎患者生活质量问卷的有效性和可靠性：系统评价和荟萃分析。
Health Qual Life Outcomes. 2022 Jul 30;20(1):116. doi: 10.1186/s12955-022-02026-5.
6
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.强直性脊柱炎管理的当前证据：针对强直性脊柱炎ASAS/EULAR管理建议的系统文献综述
Ann Rheum Dis. 2006 Apr;65(4):423-32. doi: 10.1136/ard.2005.041129. Epub 2005 Aug 26.
7
TNF ınhibitor resistance in ankylosing spondylitis: is Helicobacter pylori the overlooked culprit?强直性脊柱炎中肿瘤坏死因子抑制剂耐药性：幽门螺杆菌是被忽视的罪魁祸首吗？
Clin Rheumatol. 2025 Jun 18. doi: 10.1007/s10067-025-07536-3.
8
Optimal Biologic Drugs for the Treatment of Ankylosing Spondylitis: Results from a Network Meta-Analysis and Network Metaregression.治疗强直性脊柱炎的最佳生物制剂：一项网络荟萃分析和网络荟萃回归研究的结果。
Biomed Res Int. 2022 Jul 6;2022:8316106. doi: 10.1155/2022/8316106. eCollection 2022.
9
Effectiveness of Exercise Programs in Ankylosing Spondylitis: A Meta-Analysis of Randomized Controlled Trials.运动方案治疗强直性脊柱炎的疗效：一项随机对照试验的荟萃分析。
Arch Phys Med Rehabil. 2018 Feb;99(2):383-389.e1. doi: 10.1016/j.apmr.2017.07.015. Epub 2017 Aug 30.
10
Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials.通过对已发表的随机对照试验的疗效数据进行混合治疗比较，间接比较抗 TNF 生物制剂在强直性脊柱炎患者中的疗效。
J Med Econ. 2012;15(3):473-80. doi: 10.3111/13696998.2012.660255. Epub 2012 Feb 16.
本文引用的文献
1
Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13.使用英夫利昔单抗生物类似药CT-P13治疗的强直性脊柱炎患者中与抗药抗体产生相关的因素。
J Rheum Dis. 2025 Apr 1;32(2):136-144. doi: 10.4078/jrd.2024.0114. Epub 2025 Jan 16.
2
Korean treatment recommendations for patients with axial spondyloarthritis.韩国关于中轴型脊柱关节炎患者的治疗建议。
J Rheum Dis. 2023 Jul 1;30(3):151-169. doi: 10.4078/jrd.2023.0025.
3
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove.针对阿达木单抗的抗药物抗体的产生与 HLA-DR 肽结合槽内的变异有关。
JCI Insight. 2023 Feb 22;8(4):e156643. doi: 10.1172/jci.insight.156643.
4
Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study.肿瘤坏死因子抑制剂（TNFi）抗药抗体、吸烟与炎性关节炎患者疾病活动度之间的关联：一项挪威横断面观察性研究的结果
Rheumatol Ther. 2022 Aug;9(4):1171-1179. doi: 10.1007/s40744-022-00464-7. Epub 2022 May 20.
5
Immunogenicity of TNF-Inhibitors.肿瘤坏死因子抑制剂的免疫原性。
Front Immunol. 2020 Feb 26;11:312. doi: 10.3389/fimmu.2020.00312. eCollection 2020.
6
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial.甲氨蝶呤对阿达木单抗治疗中轴型脊柱关节炎的免疫原性和长期维持效果的影响：一项多中心随机试验。
RMD Open. 2020 Jan;6(1). doi: 10.1136/rmdopen-2019-001047. Epub 2020 Jan 9.
7
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.2019 年美国风湿病学会/脊柱关节炎协会/脊柱关节炎研究和治疗网络关于治疗强直性脊柱炎和非放射学中轴型脊柱关节炎的建议更新。
Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042. Epub 2019 Aug 22.
8
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.类风湿关节炎中阿达木单抗和英夫利昔单抗抗药物抗体的发生率和危险因素：一项欧洲回顾性多队列分析。
Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12.
9
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.在类风湿关节炎和银屑病试验中，原研 TNF 抑制剂和生物类似药的疗效和安全性结局：系统文献回顾。
BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.
10
Identification of HLA-DRB1 association to adalimumab immunogenicity.鉴定阿达木单抗免疫原性与 HLA-DRB1 关联性。
PLoS One. 2018 Apr 3;13(4):e0195325. doi: 10.1371/journal.pone.0195325. eCollection 2018.
Zotero 插件